Analysts for the banks noted the large addressable market for the company's cancer screening tests as well as the benefits of its commercialization deals with Abbott and Roche.

NEW YORK – Proteotype Diagnostics is barreling toward the clinical market with a new study planned for Enlighten, its multicancer early detection test, while another study is set to commence that will ...

There was a noticeable uptick in digital pathology devices and software clearances among more than a dozen 510(k)s granted by the agency last month.

An analyst with investment bank Leerink partners noted that Freenome is addressing a significant total addressable market in liquid biopsy cancer screening.

LisenID uses a biomarker called loss of imprinting to apply to ambiguous biopsy results and return a diagnosis of lung cancer.

Natera's tissue-free assay Latitude will be used in Kupando's clinical trial of its lead immunotherapy candidate KUP-101.

The clearances include one for an AI-assisted quality control software that detects six common whole-slide image artifacts.

Recent catalysts such as an FDA approval, NCCN guideline inclusion, and Japanese regulatory approval have fueled the firm's goals to expand its presence.

Natera's Q2 net loss was $67.0 million, or $.47 per share, compared to a net loss of $100.9 million, or $.74 per share, in Q2 of last year. On average, analysts had expected a loss of $.53 per share.